[Adjuvant therapy of osteogenic osteosarcomas of the limb: results of the SO4 78 trial].
Twenty-nine patients with osteogenic osteosarcoma of a limb underwent both pulmonary radiotherapy and chemotherapy immediately after treatment of the primary tumor, mainly by radical surgery or radiotherapy (80 grays/tumor). Chemotherapy consisted of alternate A and B cycles every four weeks and BCG scarifications between cycles. Cycle A combines vincristine, ameticine, methotrexate and folinic acid; cycle B consists of adriamycin, vincristine, imidazole carboxamide and cyclophosphamide. A 20 gray irradiation was delivered to the thorax between the first A and B cycles. 50% of patients had no local recurrence or metastases after three years. 70% are alive at three years. Toxicity of this protocol is mainly hematologic and bronchopulmonary (with one fatal infection). Alopecia and minor digestive toxicity were recorded in all patients. Severe cardiotoxicity was seen in only one case. Longer follow-up is needed to evaluate long-term toxicity, particularly bronchopulmonary side-effects.
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000628:therapy; D002986:Clinical Trials as Topic; D005121:Extremities; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control; D012516:Osteosarcoma / Q000188:drug therapy* / Q000628:therapy
Traitement adjuvant des sarcomes ostéogéniques des membres: résultats de l'essai SO4 78.